NASDAQ:ALLKAllakos Stock Price, Forecast & News

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALLK stock has increased by 31.3% and is now trading at $76.56. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allakos.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Allakos.

Allakos Inc (NASDAQ:ALLK) issued its earnings results on Monday, May, 11th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.01. View Allakos' earnings history.

3 Wall Street analysts have issued 12 month price objectives for Allakos' stock. Their forecasts range from $36.00 to $94.00. On average, they anticipate Allakos' stock price to reach $65.00 in the next year. This suggests that the stock has a possible downside of 15.1%. View analysts' price targets for Allakos.

Press coverage about ALLK stock has been trending somewhat positive on Monday, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allakos earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAllakos.

Allakos saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 7,770,000 shares, a decline of 5.1% from the April 15th total of 8,190,000 shares. Based on an average daily volume of 411,400 shares, the short-interest ratio is currently 18.9 days. Approximately 32.6% of the company's shares are short sold. View Allakos' Current Options Chain.

Some companies that are related to Allakos include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Ascendis Pharma A/S (ASND) and Autolus Therapeutics (AUTL).

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.32%), Capital World Investors (10.70%), Capital International Investors (7.32%), BlackRock Inc. (6.15%), Redmile Group LLC (6.10%) and State Street Corp (1.66%). Company insiders that own Allakos stock include Daniel Janney, John P Mckearn and Venture Fund (Ohi Rivervest II. View institutional ownership trends for Allakos.

ALLK stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Cormorant Asset Management LP, Redmile Group LLC, Bank of New York Mellon Corp, Tekla Capital Management LLC, Deutsche Bank AG, Legal & General Group Plc, and Wells Fargo & Company MN. Company insiders that have sold Allakos company stock in the last year include John P Mckearn, and Venture Fund (Ohi Rivervest II. View insider buying and selling activity for Allakos.

ALLK stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Wellington Management Group LLP, BlackRock Inc., Eventide Asset Management LLC, Capital Research Global Investors, Pictet Asset Management Ltd., Handelsbanken Fonder AB, and Alliancebernstein L.P.. Company insiders that have bought Allakos stock in the last two years include Daniel Janney, and Venture Fund (Ohi Rivervest II. View insider buying and selling activity for Allakos.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLK stock can currently be purchased for approximately $76.56.

Allakos has a market capitalization of $3.73 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe.

The official website for Allakos is www.allakos.com.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]